[go: up one dir, main page]

GB0308466D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0308466D0
GB0308466D0 GBGB0308466.2A GB0308466A GB0308466D0 GB 0308466 D0 GB0308466 D0 GB 0308466D0 GB 0308466 A GB0308466 A GB 0308466A GB 0308466 D0 GB0308466 D0 GB 0308466D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0308466.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0308466.2A priority Critical patent/GB0308466D0/en
Publication of GB0308466D0 publication Critical patent/GB0308466D0/en
Priority to CN201110166417A priority patent/CN102267988A/en
Priority to EP04726485.8A priority patent/EP1615898B1/en
Priority to PCT/EP2004/003819 priority patent/WO2004089913A1/en
Priority to JP2006505087A priority patent/JP4619356B2/en
Priority to AU2004228352A priority patent/AU2004228352B2/en
Priority to BRPI0409314-3A priority patent/BRPI0409314A/en
Priority to ES04726485.8T priority patent/ES2527882T3/en
Priority to US10/552,317 priority patent/US7615562B2/en
Priority to MXPA05010899A priority patent/MXPA05010899A/en
Priority to CA002521340A priority patent/CA2521340A1/en
Priority to CNA2004800160503A priority patent/CN1802357A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
GBGB0308466.2A 2003-04-11 2003-04-11 Organic compounds Ceased GB0308466D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0308466.2A GB0308466D0 (en) 2003-04-11 2003-04-11 Organic compounds
CNA2004800160503A CN1802357A (en) 2003-04-11 2004-04-08 2-aminopyrimidine derivatives and their medical use
JP2006505087A JP4619356B2 (en) 2003-04-11 2004-04-08 Aminopyrimidine derivatives and their medical use
EP04726485.8A EP1615898B1 (en) 2003-04-11 2004-04-08 2-Aminopyrimidine derivatives and their medical use
PCT/EP2004/003819 WO2004089913A1 (en) 2003-04-11 2004-04-08 Aminopyrimidine derivatives and their medical use
CN201110166417A CN102267988A (en) 2003-04-11 2004-04-08 2-aminopyrimidine derivatives and their medical use
AU2004228352A AU2004228352B2 (en) 2003-04-11 2004-04-08 Aminopyrimidine derivatives and their medical use
BRPI0409314-3A BRPI0409314A (en) 2003-04-11 2004-04-08 2-aminopyrimidine derivatives and their medical use
ES04726485.8T ES2527882T3 (en) 2003-04-11 2004-04-08 Derivatives of 2-aminopyrimidine and its medical use
US10/552,317 US7615562B2 (en) 2003-04-11 2004-04-08 2-aminopyrimidine derivatives and their medical use
MXPA05010899A MXPA05010899A (en) 2003-04-11 2004-04-08 Aminopyrimidine derivatives and their medical use.
CA002521340A CA2521340A1 (en) 2003-04-11 2004-04-08 Aminopyrimidine derivatives and their medical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308466.2A GB0308466D0 (en) 2003-04-11 2003-04-11 Organic compounds

Publications (1)

Publication Number Publication Date
GB0308466D0 true GB0308466D0 (en) 2003-05-21

Family

ID=9956663

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0308466.2A Ceased GB0308466D0 (en) 2003-04-11 2003-04-11 Organic compounds

Country Status (11)

Country Link
US (1) US7615562B2 (en)
EP (1) EP1615898B1 (en)
JP (1) JP4619356B2 (en)
CN (2) CN102267988A (en)
AU (1) AU2004228352B2 (en)
BR (1) BRPI0409314A (en)
CA (1) CA2521340A1 (en)
ES (1) ES2527882T3 (en)
GB (1) GB0308466D0 (en)
MX (1) MXPA05010899A (en)
WO (1) WO2004089913A1 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390670B2 (en) * 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
WO2005040133A1 (en) * 2003-10-23 2005-05-06 Pharmacia Corporation Pyrimidine compounds for the treatment of inflammation
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
JP2007531757A (en) * 2004-03-30 2007-11-08 カイロン コーポレイション Substituted thiophene derivatives as anticancer agents
MXPA06013918A (en) * 2004-06-18 2007-03-07 Neurosearch As Novel alkyl substituted piperidine derivatives as monoamine neurotransmitter re-uptake inhibitors.
AR050253A1 (en) * 2004-06-24 2006-10-11 Smithkline Beecham Corp COMPOSITE DERIVED FROM INDAZOL CARBOXAMIDE, COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
WO2006010431A1 (en) 2004-07-28 2006-02-02 Merck Patent Gmbh Transflective lcd comprising a patterned retardation film
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
GB0427381D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
DE102005025225A1 (en) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Process for the preparation of 2- (2-amino-pyrimidin-4-yl) -1H-indole-5-carboxylic acid derivatives
TWI380973B (en) 2005-06-30 2013-01-01 Smithkline Beecham Corp Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
NZ567133A (en) * 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
NZ601687A (en) 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
DE102006012617A1 (en) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
EP2018380B1 (en) * 2006-05-19 2011-10-19 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
JP2009542604A (en) * 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4-Heterocycloalkylpyrimidines, their preparation and use as pharmaceuticals
CA2658764A1 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
EP2066319B1 (en) 2006-09-08 2012-02-01 F. Hoffmann-La Roche AG Benzotriazole kinase modulators
US20080176891A1 (en) * 2006-09-22 2008-07-24 Paul Bamborough Novel compounds
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
CN101678022A (en) 2006-12-21 2010-03-24 弗特克斯药品有限公司 5-cyano-4- (pyrrolo [2,3b ] pyridin-3-yl) pyrimidine derivatives useful as protein kinase inhibitors
ATE479680T1 (en) 2006-12-21 2010-09-15 Lilly Co Eli IMIDAZOLIDINONYLAMINOPYRIMIDINE COMPOUNDS FOR TREATING CANCER
EA016178B1 (en) 2006-12-21 2012-02-28 Эли Лилли Энд Компани Imidazolidinonyl aminopyrimidine compounds
FR2911140B1 (en) * 2007-01-05 2009-02-20 Sanofi Aventis Sa NOVEL 2-ANILINO 4-HETEROARYL PYRIMIDES DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR AS INHIBITORS OF IKK
DE102007008419A1 (en) 2007-02-21 2008-08-28 Merck Patent Gmbh 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
JP2010526781A (en) * 2007-04-30 2010-08-05 アボット・ラボラトリーズ Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
TW200908981A (en) 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds
EP2155735A2 (en) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl aminopyrimidine compounds
DE102007028515A1 (en) 2007-06-21 2008-12-24 Merck Patent Gmbh 6- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
CA2693594A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
ES2535166T3 (en) * 2007-09-04 2015-05-06 The Scripps Research Institute Substituted pyrimidinyl amines as protein kinase inhibitors
DE102008005493A1 (en) 2008-01-22 2009-07-23 Merck Patent Gmbh 4- (Pyrrolo [2,3-c] pyridines-3-yl) -pyrimidin-2-yl-amine derivatives
TW200951114A (en) 2008-05-20 2009-12-16 Astrazeneca Ab Phenyl or pyridinyl substituted indazoles derivatives
DE102008031517A1 (en) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amine derivatives
AU2009298981B2 (en) 2008-10-02 2012-09-27 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2011060295A1 (en) * 2009-11-13 2011-05-19 Genosco Kinase inhibitors
DE102009060174A1 (en) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amine derivatives
DE102009060175A1 (en) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo [2,3-d] pyrazine-7-yl-pyrimidine compounds
AU2010339531A1 (en) 2009-12-30 2012-08-23 Arqule, Inc. Substituted naphthalenyl-pyrimidine compounds
CN102821759A (en) 2010-03-30 2012-12-12 诺华有限公司 PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
AU2010351938B2 (en) 2010-04-27 2014-10-30 Hutchison Medipharma Limited Pyrimidinyl indole compounds
JP2013147428A (en) * 2010-04-27 2013-08-01 Dainippon Sumitomo Pharma Co Ltd Novel 2-heteroaryl monocyclic pyrimidine derivative
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
DE102010050558A1 (en) 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-pyrrolo [2,3-b] pyridine
DE102010053347A1 (en) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-hetaryl-substituted pyrrolo [2,3-b] pyridine-derivative as PDK1 inhibitors
AU2011338389A1 (en) * 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
KR20140014110A (en) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of influenza viruses replication
US9295754B2 (en) 2011-02-24 2016-03-29 Emory University Noggin inhibitory compositions for ossification and methods related thereto
CA2830780A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
WO2013043529A1 (en) 2011-09-19 2013-03-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
JP6250561B2 (en) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Heteroaryl compounds and methods for their use
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
ES2741444T3 (en) 2013-11-13 2020-02-11 Vertex Pharma Inhibitors of influenza virus replication
MX2016000701A (en) 2015-01-22 2016-11-24 Evonik Degussa Gmbh Method for producing an n-methyl substituted triacetone amine compound.
MX374426B (en) 2015-01-22 2025-03-06 Evonik Operations Gmbh SYNTHESIS OF TRIACETONADIAMINE COMPOUNDS BY REDUCTIVE AMINATION PROCEDURE OF TRIACETONADIAMINE AND DERIVATIVES THEREOF.
PL3277284T3 (en) 2015-04-02 2021-03-08 Proximagen, Llc Novel therapies for cancer
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
DE102016212378A1 (en) 2016-07-07 2018-01-11 Evonik Degussa Gmbh Synthesis of triacetonediamine compounds by reductive amination starting from triacetonediamine and its derivatives
DE102016212379A1 (en) 2016-07-07 2018-01-11 Evonik Degussa Gmbh Process for the preparation of an N-methyl-substituted triacetoneamine compound
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. CONNECTIONS AND COMPOSITIONS AND USES THEREOF
JP7187437B2 (en) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク Compounds and compositions and uses thereof
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
AU2018352695A1 (en) * 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
AU2019209470A1 (en) 2018-01-16 2020-08-13 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2019143730A1 (en) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
GEP20227433B (en) 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
CN112823159B (en) * 2018-09-21 2024-03-01 上海轶诺药业有限公司 Aromatic heterocyclic compounds with kinase inhibitory activity
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
BR112021008516A2 (en) * 2018-11-01 2021-09-14 Syros Pharmaceuticals, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS (CDK 7)
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
KR20210139376A (en) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 Salts of isochromanyl compounds, and crystalline forms thereof, methods of preparation, therapeutic uses and pharmaceutical compositions
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (en) 2019-10-11 2022-12-23 Incyte Corp BICYCLIC AMINES AS INHIBITORS OF CDK2
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2022063212A1 (en) * 2020-09-24 2022-03-31 广州费米子科技有限责任公司 Pyrimidyl derivative, preparation method therefor and use thereof
WO2022111499A1 (en) * 2020-11-26 2022-06-02 深圳铂立健医药有限公司 Amide compound, pharmaceutical composition and use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023049691A1 (en) * 2021-09-23 2023-03-30 Zeno Management, Inc. Cdk7 inhibitors and methods of treating cancer
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114621206B (en) * 2022-03-24 2023-11-24 安徽医科大学 A 5-substituted pyrimidinediamine derivative and its preparation method and application

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
NZ334921A (en) 1996-10-15 2001-03-30 G Use of cyclooxygenase-2 inhibitors for the treatment and preparation of a medicament for prevention of neoplasia
CZ2002534A3 (en) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitors of protein-kinases, pharmaceutical preparations in which they are comprised as well as their use
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
WO2002064096A2 (en) * 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US7138403B2 (en) * 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US6821971B2 (en) * 2001-09-20 2004-11-23 The Procter & Gamble Company Fused pyrazolone compounds which inhibit the release of inflammatory cytokines
CA2526285A1 (en) * 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same

Also Published As

Publication number Publication date
ES2527882T3 (en) 2015-02-02
EP1615898A1 (en) 2006-01-18
AU2004228352A1 (en) 2004-10-21
JP4619356B2 (en) 2011-01-26
CA2521340A1 (en) 2004-10-21
CN102267988A (en) 2011-12-07
CN1802357A (en) 2006-07-12
MXPA05010899A (en) 2005-11-25
JP2006522768A (en) 2006-10-05
US20070043048A1 (en) 2007-02-22
US7615562B2 (en) 2009-11-10
AU2004228352B2 (en) 2008-03-06
EP1615898B1 (en) 2014-10-29
BRPI0409314A (en) 2006-04-25
WO2004089913A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
GB0321710D0 (en) Organic compounds
GB0308466D0 (en) Organic compounds
GB0301259D0 (en) Organic compounds
GB0303503D0 (en) Organic compounds
GB0306715D0 (en) Organic compounds
GB0302876D0 (en) Organic compounds
GB0300095D0 (en) Organic compounds
GB0315745D0 (en) Organic compounds
GB0302748D0 (en) Organic compounds
GB0323202D0 (en) Organic compounds
GB0301938D0 (en) Organic compounds
GB0303506D0 (en) Organic compounds
GB0312086D0 (en) Organic compounds
GB0306071D0 (en) Organic compounds
GB0306070D0 (en) Organic compounds
GB0302991D0 (en) Organic compounds
GB0307277D0 (en) Organic compounds
GB0307440D0 (en) Organic compounds
GB0329494D0 (en) Organic compounds
GB0303095D0 (en) Organic compounds
GB0301262D0 (en) Organic compounds
GB0301470D0 (en) Organic compounds
GB0301561D0 (en) Organic compounds
GB0301692D0 (en) Organic compounds
GB0300591D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)